Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 9, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Yigal Nochomovitz Maintained (SNDX) at Strong Buy with Decreased Target to $30 on, May 9th, 2024
Yigal Nochomovitz of Citigroup, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Decreased Target from $32 to $30 on, May 9th, 2024.
Yigal has made no other calls on SNDX in the last 4 months.
There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 1 agrees with Yigal's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- George Farmer of "Scotiabank" Downgraded from Buy to Hold and Decreased Target to $23 on, Wednesday, January 31st, 2024
This is the rating of the analyst that currently disagrees with Yigal
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $34 on, Wednesday, March 20th, 2024
